Skip to main content
Premium Trial:

Request an Annual Quote

Luminex Lines up ViraCor as First RVP Dx Provider

NEW YORK (GenomeWeb News) – A day after Luminex’s respiratory viral panel got the nod from the US Food and Drug Administration, the company signed up ViraCor Laboratories as the first national reference lab to offer the test, ViraCor said today.
 
As GenomeWeb Daily News reported Thursday, Luminex’s xTAG RVP detects 12 major respiratory viruses and subtypes from one sample, including adenovirus, three strains of influenza A, rhinovirus, and others.
 
The panel’s sensitivity and specificity “helps eliminate incorrect diagnosis by greatly reducing false negative results that are common with conventional testing methods,” said ViraCor VP and CSO Steve Kleiboeker.
 
Viacor noted that it offers a 24-hour turnaround time on tests.
 
Financial terms of the agreement were not released.
The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.